See more : Grieg Seafood ASA (GRGSF) Income Statement Analysis – Financial Results
Complete financial analysis of Certara, Inc. (CERT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Certara, Inc., a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
- Orient Corporation (8585.T) Income Statement Analysis – Financial Results
- Asahi Holdings, Inc. (5857.T) Income Statement Analysis – Financial Results
- TNF Pharmaceuticals, Inc. (TNFA) Income Statement Analysis – Financial Results
- MISUMI Group Inc. (9962.T) Income Statement Analysis – Financial Results
- Tian An China Investments Company Limited (0028.HK) Income Statement Analysis – Financial Results
Certara, Inc. (CERT)
Industry: Medical - Healthcare Information Services
Sector: Healthcare
Website: https://www.certara.com
About Certara, Inc.
Certara, Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. Further, company offers software, comprising mechanistic biosimulation platform, empirical PK/PD biosimulation platform, data standardization and compliance software, scientific informatics platform, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions platform, and market access communication platform. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
---|---|---|---|---|---|---|
Revenue | 354.34M | 335.64M | 286.10M | 243.53M | 208.51M | 163.72M |
Cost of Revenue | 141.02M | 132.58M | 111.62M | 100.77M | 79.77M | 71.04M |
Gross Profit | 213.32M | 203.07M | 174.49M | 142.77M | 128.74M | 92.68M |
Gross Profit Ratio | 60.20% | 60.50% | 60.99% | 58.62% | 61.74% | 56.61% |
Research & Development | 34.17M | 28.21M | 20.38M | 19.64M | 11.63M | 10.48M |
General & Administrative | 95.39M | 71.77M | 79.54M | 88.48M | 47.93M | 43.39M |
Selling & Marketing | 32.02M | 27.41M | 20.14M | 19.20M | 10.73M | 9.42M |
SG&A | 127.41M | 99.18M | 99.68M | 107.68M | 58.66M | 52.81M |
Other Expenses | 92.51M | 43.16M | 40.85M | 39.86M | 38.84M | -107.00K |
Operating Expenses | 254.09M | 170.55M | 160.91M | 167.19M | 109.13M | 97.33M |
Cost & Expenses | 395.11M | 303.12M | 272.53M | 267.95M | 188.90M | 168.37M |
Interest Income | 0.00 | 17.77M | 16.84M | 25.30M | 28.00M | 0.00 |
Interest Expense | 22.92M | 17.77M | 16.84M | 25.30M | 28.00M | 27.80M |
Depreciation & Amortization | 56.07M | 52.47M | 45.12M | 42.75M | 41.56M | 37.01M |
EBITDA | 23.84M | 89.00M | 58.58M | 17.87M | 60.41M | 32.25M |
EBITDA Ratio | 6.73% | 26.52% | 20.47% | 7.34% | 28.97% | 19.70% |
Operating Income | -40.77M | 32.52M | 13.58M | -24.89M | 19.61M | -4.65M |
Operating Income Ratio | -11.51% | 9.69% | 4.75% | -10.22% | 9.41% | -2.84% |
Total Other Income/Expenses | -14.37M | -13.77M | -16.95M | -25.76M | -28.76M | -27.91M |
Income Before Tax | -55.14M | 18.76M | -3.38M | -50.18M | -9.15M | -32.56M |
Income Before Tax Ratio | -15.56% | 5.59% | -1.18% | -20.61% | -4.39% | -19.89% |
Income Tax Expense | 214.00K | 4.02M | 9.89M | -784.00K | -225.00K | 697.00K |
Net Income | -55.36M | 14.73M | -13.27M | -49.40M | -8.93M | -33.26M |
Net Income Ratio | -15.62% | 4.39% | -4.64% | -20.28% | -4.28% | -20.31% |
EPS | -0.35 | 0.09 | -0.09 | -0.32 | -0.06 | -0.25 |
EPS Diluted | -0.35 | 0.09 | -0.09 | -0.32 | -0.06 | -0.25 |
Weighted Avg Shares Out | 158.94M | 156.88M | 149.84M | 152.98M | 157.34M | 132.41M |
Weighted Avg Shares Out (Dil) | 158.94M | 159.35M | 149.84M | 152.98M | 157.34M | 132.41M |
Certara to Participate in Upcoming Investor Conferences
Certara Simcyp™ Group Awarded Two New Grants from US FDA
Certara stock drops after biotech software company misses profit target
Certara Inc. (CERT) Q2 2023 Earnings Call Transcript
Certara Reports Second Quarter 2023 Financial Results
Certara & Xybion Partner to Integrate Nonclinical R&D Software to Streamline Assessing Drug Safety & Efficacy
Certara collaborates with Korea Institute of Toxicology to ensure FDA submission-ready SEND dataset
Certara to Report Second Quarter 2023 Financial Results on August 9th, 2023
Certara to Participate in the Jefferies Global Healthcare Conference
Certara, Inc. (CERT) Q1 2023 Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports